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Vasoactive intestinal peptide has been suggested to
play some roles in in¯ammatory dermatoses such as
atopic dermatitis and psoriasis. The aim of this study
is to clarify the precise mechanisms of how vaso-
active intestinal peptide is implicated in the patho-
genesis of these disorders. We investigated the
expression of vasoactive intestinal peptide and its
receptors in normal human ®broblasts and keratino-
cytes, as well as in a human epidermal keratinocyte
cell line DJM-1, using reverse transcription polymer-
ase chain reaction and northern blotting. Type I VIP
receptor mRNA was expressed in normal human
keratinocytes and DJM-1 cells, and the latter also
expressed type II receptor in lesser amounts. Neither
type I nor type II VIP receptor mRNA was detected
in ®broblasts, and vasoactive intestinal peptide tran-
script was not found in any cells examined. Type I
VIP receptor mRNA was upregulated by Th1 cyto-
kines (interferon-g), Th2 cytokines (interleukin-4),
and tumor necrosis factor a, as well as vasoactive
intestinal peptide itself, suggesting the presence of an
autoregulatory loop. Vasoactive intestinal peptide
increased cAMP production and cell proliferation of
DJM-1 cells, and also induced the production of
in¯ammatory cytokines such as interleukin-6, inter-
leukin-8, and RANTES. The production of cAMP
and cytokines was abrogated by a type I VIP recep-
tor selective antagonist, indicating that type I recep-
tor mediates these effects. Overall, these results
suggest that upregulation of vasoactive intestinal
peptide receptors by cytokines from in¯ammatory
cells in the dermis enhances the proliferation and
cytokine production of keratinocytes in response to
vasoactive intestinal peptide from nerve endings.
This cytokine network around keratinocytes may be
involved in the pathogenesis of in¯ammatory derma-
toses. Key words: chemokines/dermatoses/neuropeptides/
skin. J Invest Dermatol 116:743±749, 2001
R
ecently, evidence has been accumulating that the
nervous system modulates various immunologic
responses, including certain in¯ammatory events,
in the skin. Neuropeptides released from nerves
innervating the skin mediate these responses by
regulating functions of keratinocytes, Langerhans cells, mast cells,
dermal microvascular endothelial cells, and in®ltrating immune
cells (Scholzen et al, 1998). Vasoactive intestinal peptide (VIP) is a
neuropeptide distributed in the central and peripheral nervous
systems as well as in a wide variety of peripheral tissues and organs
(Bellinger et al, 1996). In the skin, VIP is one of the major
neuropeptides released from both autonomic and sensory nerve
®bers (Bjorklund et al, 1986). Its role in the immune system is
thought to be primarily anti-in¯ammatory (Ganea and Sun, 1993).
VIP also exerts many important physiologic functions, however,
including vasodilatation (Nilsson and Maepea, 1987), plasma
extravasation, mast cell degranulation (Lowman et al, 1988), and
immunomodulation (Lotti et al, 1995). In recent years, many
reports suggest active roles for VIP in the pathogenesis of
in¯ammatory skin disorders such as atopic dermatitis and psoriasis.
A crosstalk between epidermis and dermis is important in the
development of skin diseases. It is likely that neuropeptides and/or
cytokines released from nerve endings, mast cells, and lymphocytes
in the dermis modulate the function of keratinocytes. On the other
hand, epidermal cytokines may also in¯uence the dermis. For
example, they alter cytokine production from the immune cells,
®broblasts, and endothelial cells in the dermis. Lundeberg and
Nordlind (1999) ®rst demonstrated the presence of VIP receptors in
the basal layer of the epidermis by immunohistochemistry. It is
therefore possible that VIP, released from nerve endings in the
dermis as well as in the epidermis, binds to its receptor on
keratinocytes and modulates the functions of keratinocytes such as
cytokine production.
The aim of this study was to clarify the roles of neuropeptides in
the pathogenesis of in¯ammatory skin disorders by analyzing the
interplay between VIP and keratinocytes. Initially, we examined
the expression and regulation of VIP receptors on keratinocytes
using cultured normal keratinocytes and a human epidermal
keratinocyte cell line DJM-1. Next, we examined the effects of
VIP on biologic activities of keratinocytes including cAMP
production, cell proliferation, and cytokine production using
DJM-1 cells. The results obtained suggest the presence of a
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cytokine network around keratinocytes, which may be involved in
the pathogenesis of in¯ammatory dermatoses.
MATERIALS AND METHODS
Reagents VIP and forskolin were purchased from Sigma (St. Louis,
MO). VIP receptor antagonist ([4-Cl-D-Phe6, Leu17]-VIP) was
purchased from Peninsula Laboratories (San Caros, CA). Recombinant
human interleukin-4 (IL-4), tumor necrosis factor a (TNF-a), and
interferon-g (IFN-g) were obtained from PeproTech (London, U.K.).
Speci®c antirabbit polyclonal antibodies against IL-6 (H-183) and IL-8
(H-60) are products of Santa Cruz Biotechnology (Santa Cruz, CA).
Cells and cell culture The human epidermal keratinocyte cell line
DJM-1 was established from human skin squamous cell carcinoma by
Kitajima et al (1987). This cell line was maintained routinely in
Dulbecco's modi®ed Eagle's medium (DMEM) (Life Technologies,
Grand Island, NY) supplemented with 10% fetal bovine serum (FBS)
(ICN Biomedicals, Aurora, OH), 10 ng per ml streptomycin, and 100 U
per ml penicillin. Cells were grown in monolayer culture at 37°C in a
humidi®ed atmosphere containing 5% CO2, and dispersed with 0.1%
trypsin, 0.02% ethylenediamine tetraacetic acid (EDTA) treatment for
subculture. Normal human dermal ®broblasts (adult human ®broblast,
Curabo, Osaka, Japan) were cultured as previously described (Shenker et
al, 1982; Weller et al, 1993). Normal human epidermal keratinocytes
(adult breast skin, Curabo) were cultured in HuMedia-KB2 (Curabo)
supplement with epidermal growth factor, insulin, hydrocortisone, and
bovine pituitary extract (HuMedia-KG, Curabo).
Cell proliferation assay After reaching con¯uence, DJM-1 cells were
detached with trypsin±EDTA solution and transferred onto 30 mm
dishes at 1.5 3 105 cells per dish. The cells were allowed to attach for
3 d in DMEM containing 10% FBS. The medium was replaced with
serum-free DMEM at day 4, and the cells were further incubated for
24 h to obtain quiescent cells. VIP was added at indicated concentrations
at day 5. A single cell suspension was made by trypsin±EDTA treatment
and subjected to cell counting after 24 h. Cell viability was always more
than 99.5%.
Measurement of 5¢-bromo-2¢-deoxyuridine (BrdU) incorpor-
ation In parallel with the measurement of cell numbers, we examined
the increment of cellular DNA with the BrdU Labeling Detection kit
(Boehringer Mannheim, Mannheim, Germany). After reaching
con¯uence, DJM-1 cells were detached with trypsin±EDTA solution,
transferred into standard 96-well microtiter plates (Becton Dickinson
Labware, Franklin Lakes, NJ) at 2 3 103 cells per well, and grown in
DMEM and 10% FBS for 24 h. The medium was then replaced with
serum-free DMEM, and the cells were further incubated for 24 h to
obtain quiescent cells. VIP was added at indicated concentrations, and
the culture was continued for 24 h. After labeling with BrdU for the
®nal 3 h, the cells were serially treated with nuclease, anti-BrdU-
peroxidase, and tetramethylbenzidine. The absorbance at 405 nm
parallels the DNA content. Four samples were analyzed in each
experiment.
cAMP assay Normal human epidermal keratinocytes were seeded at
a concentration of 1 3 104 cells per well in standard 96-well microtiter
plates and maintained in HuMedia-KB2 supplement with HuMedia-KG
for 48 h. DJM-1 cells were seeded at a concentration of 5 3 104 cells
per well in standard 96-well microtiter plates and incubated in DMEM
containing 10% FBS for 24 h. Subsequently, cells were washed twice
with physiologic saline solution (140 mM NaCl, 4.6 mM KCl, 1 mM
MgCl2, 2 mM CaCl2, 10 mM glucose, 10 mM HEPES, pH 7.4), and
incubated in the absence or presence of 1 mM VIP receptor antagonist
for 10 min at 37°C. Then, DJM-1 cells were incubated in the absence
or presence of 1 mM VIP for 10 min at 37°C. Intracellular cAMP
concentration was determined by enzyme immunoassay kit (Biotrak
cAMP EIA system, Amersham, Buckinghamshire, U.K.) according to the
manufacturer's protocol. The results were expressed as mean values of
three or four independent experiments.
Measurement of IL-1a, IL-6, IL-8, TNF-a, and RANTES
production of DJM-1 cells DJM-1 cells were seeded in 10 cm
culture dishes at 3 3 106 cells per dish, and allowed to attach for 24 h in
DMEM containing 10% FBS. Subsequently, cells were cultured in
serum-free DMEM for 24 h, and further incubated in the absence or
presence of 0.1 nM to 10 mM VIP with or without 1 mM VIP receptor
antagonist for 6 h. To determine the kinetics of cytokine production,
DJM-1 cells were incubated with 1 mM VIP for up to 24 h, and
harvested for the evaluation of IL-6, IL-8, and RANTES production at
0, 3, 6, 12, and 24 h of culture. Cytokine concentrations in supernatants
were determined by enzyme-linked immunosorbent assays. All
experiments were carried out in triplicate.
Isolation of total RNA and reverse transcription polymerase chain
reaction (RT-PCR) Cells were washed twice with ice-cold
phosphate-buffered saline (PBS), immediately harvested by scraping, and
lyzed in Isogen solution (Nippon Gene, Tokyo, Japan), which contains
phenol and guanidine isothiocyanate. RNA was precipitated with
ethanol, washed, and dissolved in diethylpyrocarbonate-treated water.
After incubation with 2 mg per ml DNase I (RNase-free) (TaKaRa,
Ohtsu, Japan) for 1 h at 37°C to avoid contamination of genomic DNA,
1 mg of total RNA was reverse transcribed into cDNA using SuperScript
reverse transcriptase and oligo(dT) primers (Life Technologies,
Gaithersburg, MD). Subsequent PCR ampli®cation was performed with
cDNA derived from 50 ng of RNA using 1 unit Taq polymerase in a 50
ml reaction mixture containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl,
1.5 mM MgCl2, and 100 mM dNTPs in the presence of speci®c primer
pairs (200 nM each) for 30 cycles. Each cycle consisted of 1 min of
denaturation at 94°C, 1 min of annealing at 60°C, and 2 min of
extension at 72°C. After agarose gel electrophoresis, PCR products were
visualized with ethidium bromide. The following oligonucleotides were
used as primers: VIP sense primer, 5¢-GCCAGGCATGCTGATGGA-
GTTTTC-3¢; VIP antisense primer, 5¢-CCTCTTTCCATTCAGAAT-
TGAGTT-3¢ (Park et al, 1996); type I VIP receptor (VIP1R) sense
primer: 5¢-CTTCTGGTCGCCACAGCTATCCTG-3¢; VIP1R anti-
sense primer 5¢-ACTGCTGTCACTCTTCCTGATATC-3¢ (Sreedharan
et al, 1993, 1995; Couvineau et al, 1994); type II VIP receptor (VIP2R)
sense primer, 5¢-CGTCACGGTGCCCTGCCCAAAAGT-3¢; VIP2R
antisense primer, 5¢-GCCCCTCCACCAGCAGCCAGAAGA-3¢ (Wei
and Mojsov, 1996); human glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) sense primer, 5¢-CCACCCATGGCAAATTCCATGGCA-3¢;
GAPDH antisense primer, 5¢-TCTAGACGGCAGGTCAGGTCCACC-
3¢. The expected fragment lengths were 231 bp, 543 bp, 464 bp, and
597 bp for VIP, VIP1R, VIP2R, and GAPDH, respectively.
Northern blot analysis DJM-1 cells were plated at 1 3 105 cells per
dish (6 cm diameter) and cultured in DMEM with 10% FBS for 24 h.
The cells were synchronized for 24 h in serum-free DMEM to obtain
quiescent cells. Subsequently, the medium was replaced with DMEM
containing effectors (1 mM VIP, 10 ng per ml TNF-a, 10 ng per ml IL-
4, or 10 ng per ml IFN-g), and incubation was continued for the
required culture periods. In control culture, the medium was simply
replaced with serum-free DMEM. RNA samples (10 mg each) were
denatured with formamide and formaldehyde at 65°C for 15 min,
electrophoresed in 1.0% agarose gels containing 6% formaldehyde,
20 mM methoxypsoralen, 5 mM sodium acetate, and 1 mM EDTA, and
blotted onto nylon membranes (Hybond-N+, Amersham). The
membranes were hybridized with VIP1R cDNA probe, and labeled with
[a-32P]dCTP (speci®c activity, 3000 Ci per mmol; Amersham) using the
oligonucleotide random priming method (Random primer DNA labeling
kit version 2; TaKaRa). A 543 bp fragment, spanning nucleotides 480±
1022 of human VIP1R cDNA, was generated by RT-PCR and used as
a probe. After hybridization, the ®lters were washed with 2 3 standard
sodium citrate (SSC) and 0.1% sodium dodecyl sulfate (SDS) at room
temperature, and then washed with 0.2 3 SSC and 0.1% SDS at 62°C.
The ®lters were exposed to Kodak X-OMAT ®lm (Eastman Kodak,
Rochester, NY) at ±70°C. The level of VIP1R mRNA expression was
quanti®ed by densitometer (CS-9000; Shimazu Seisakusyo, Tokyo,
Japan). Data are expressed as a percentage of the untreated control at
0 h.
Western blot analysis Cells were washed with ice-cold Tris-buffered
saline (TBS) [25 mM Tris-HCl (pH 8.0) and 150 mM NaCl] and lyzed
for 30 min at 4°C with lysis buffer [50 mM Tris-HCl (pH 8.0),
120 mM NaCl, 0.5% Nonidet P-40, 100 mM sodium ¯uoride, and
200 mM sodium orthovanadate] containing 10 mg each of aprotinin,
phenylmethylsulfonyl ¯uoride, and leupeptin (Sigma). Cell lysates were
centrifuged for 15 min, and the supernatants (40 mg per sample) were
loaded onto 15% SDS-polyacrylamide gels. After electrophoresis, proteins
were transferred onto nitrocellulose membranes (Hybond-ECL;
Amersham) in transfer buffer containing 25 mM Tris-HCl, 192 mM
glycine, and 20% methanol. Residual binding sites on the membranes
were blocked with 5% skim milk in TBS for more than 30 min at room
temperature. The blots were incubated with 1 mg per ml primary
antibodies for 1 h at room temperature, washed three times (5 min each)
with TBS containing 0.05% Tween-20, and probed with a 1:1000
dilution of antirabbit horseradish-peroxidase-conjugated antibody for
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40 min at room temperature. After washing, the membranes were
incubated with the enhanced chemiluminescence substrates, and exposed
to Kodak X-OMAT ®lm (Eastman Kodak) for visualization of
immunoreactive bands.
Statistical analysis The results were expressed as means 6 SD, which
represent at least three paired experiments. The unpaired Student's t test
and an analysis of multiple variance using Scheffe's method were used for
statistical comparison. A p-value of less than 0.05 was considered to be
signi®cant.
RESULTS
Expression of VIP receptors in DJM-1 cells, normal human
keratinocytes, and ®broblasts In an attempt to clarify the
roles of the VIP/VIP receptor system in the pathogenesis of skin
diseases, we ®rst examined the expression of VIP and VIP receptors
in DJM-1 cells, normal human dermal ®broblasts, and normal
human epidermal keratinocytes using RT-PCR (Fig 1A). To
verify the amounts and integrity of the samples, GAPDH mRNA
expression was simultaneously examined (Fig 1B). A 543 bp
fragment, corresponding to VIP1R transcript, was detected in both
DJM-1 cells and normal human epidermal keratinocytes. A 464 bp
fragment, which is consistent with VIP2R mRNA, was detected
only in DJM-1 cells. Additionally, the VIP1R fragment revealed a
more noticeable intensity than that of VIP2R in DJM-1 cells.
Normal human dermal ®broblasts did not express either VIP1R or
VIP2R. A 231 bp VIP fragment was not detected in any of these
cells. These results suggest that VIP acts on normal human
epidermal keratinocytes through VIP1R, and on DJM-1 cells
through VIP1R and VIP2R. In contrast, VIP does not act on
dermal ®broblasts because receptors for VIP are lacking on the
surface.
To con®rm that VIP1R on DJM-1 cells is functionally active,
we examined the effects of VIP on VIP1R mRNA expression in
DJM-1 cells by northern blotting (Fig 2A). As a control, VIP1R
expression was simultaneously examined in untreated DJM-1 cells
(Fig 2B). The amounts of VIP1R transcript (about 4.0 kb)
markedly increased in VIP-treated cells and reached its maximum
(650% of the untreated control, Fig 2D) after 6 h treatment with
VIP. This indicates that the amounts of VIP1R on DJM-1 cells are
suf®cient to work physiologically, and VIP actually functions via
VIP1R on keratinocytes.
Effects of VIP on cAMP production, cell proliferation, and
DNA synthesis To investigate whether VIP exerts biologic
effects on keratinocytes, we examined cAMP production and cell
growth of DJM-1 cells and normal human epidermal keratinocytes
incubated with various concentrations of VIP (0.01, 0.1, and
1 mM). As a positive control, the same experiments were carried
out in the presence of forskolin. cAMP is well known as a second
messenger of VIP-receptor-mediated signal transduction
(Haegerstrand et al, 1989). As anticipated, intracellular cAMP
levels markedly increased at 10 min after the addition of as little as
0.01 mM VIP in both DJM-1 cells and normal human epidermal
keratinocytes (Fig 3). Taking into account the cell numbers in
culture plates, the increased amounts of cAMP per cell were almost
identical between DJM-1 cells and normal human epidermal
keratinocytes. Consequently, we tried to reveal the growth-
stimulatory properties of VIP for keratinocytes. As shown in
Fig 4(A), VIP slightly but signi®cantly enhanced cell proliferation
of DJM-1 cells at 0.1 mM (p < 0.05). Furthermore, VIP also
stimulated DNA synthesis at 0.1±1 mM (p < 0.05) as revealed by
BrdU incorporation assay (Fig 4B).
Inhibitory effects of VIP receptor antagonist on VIP-
stimulated cAMP production To determine which type of
receptors transduce VIP signals in keratinocytes, we examined the
effects of VIP receptor antagonist on VIP-stimulated cAMP
production in DJM-1 cells and normal human epidermal
keratinocytes. Cells were preincubated with 1 mM [4-Cl-Phe6,
Leu17]-VIP, a speci®c antagonist for VIP1R (VIP1R antagonist)
(Pandol et al, 1986; Usdin et al, 1994), and cAMP level was
evaluated after stimulation with VIP. Figure 3 shows that VIP1R
antagonist almost completely abrogated VIP-induced cAMP
production in both cells. These ®ndings indicate that VIP
mediates signal transduction through VIP1R in keratinocytes.
Figure 1. RT-PCR analysis for the expres-
sion of VIP and VIP receptors in DJM-1
cells, keratinocytes, and ®broblasts. Total
RNA extracted from DJM-1 cells, normal human
epidermal keratinocytes, and normal human
dermal ®broblasts was subjected to RT-PCR
analysis for VIP (A, lane a), VIP1R (A, lane b),
VIP2R (A, lane c), and GAPDH (B: lane 1, DJM-
1 cells; lane 2, normal human epidermal
keratinocytes; lane 3, normal human dermal
®broblasts). PCR products were visualized by
agarose gel electrophoresis in the presence of
ethidium bromide. M, molecular size marker. The
predicted sizes of PCR products are 231 bp,
543 bp, 464 bp, and 597 bp for VIP, VIP1R,
VIP2R, and GAPDH, respectively.
Figure 2. The effects of VIP on VIP1R mRNA expression in
DJM-1 cells. After starvation, DJM-1 cells were incubated with (A) or
without (B) 1 mM VIP for indicated periods. Subsequently, total cellular
RNA was extracted and subjected to northern blotting for VIP1R
expression. Ethidium bromide staining of 28 s and 18 s rRNAs is shown
as a loading control for northern blot (C). Signal intensity of each band
was quanti®ed by densitometric analysis (D). The relative densitometric
values of VIP-treated DJM-1 cells at each time point are expressed as a
percentage of the value of untreated DJM-1 cells at 0 h.
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Effects of cytokines on VIP1R mRNA expression in DJM-1
cells We examined the expression of VIP1R mRNA in DJM-1
cells treated with IL-4, TNF-a, and IFN-g at optimal
concentrations for different periods (0±48 h). The amounts of
VIP1R transcript increased after 6 h of treatment with IL-4 (230%,
180%, and 200% of the untreated control at 6 h, 12 h, and 24 h,
respectively) (Fig 5A, E). The amounts of VIP1R transcript also
increased in a time-dependent manner after TNF-a treatment
(200%, 320%, and 500% of the untreated control at 6 h, 12 h, and
24 h, respectively) (Fig 5B, E). VIP1R was upregulated at 1 h
(120% of untreated control) and reached a maximum at 3 h (240%),
which then returned to the basal level 24 h after treatment with
IFN-g (Fig 5C, E).
Measurement of cytokine production from VIP-treated
DJM-1 cells We examined the effects of VIP on the
production of various cytokines and chemokines from DJM-1
cells using enzyme-linked immunosorbent assays. IL-6, IL-8, and
RANTES contents signi®cantly increased in culture supernatants of
DJM-1 cells treated with as little as 0.1 nM VIP (IL-6 and IL-8) or
1 nM (RANTES) to 10 mM (Figs 6A, 7A, 8A). IL-1a and
TNF-a were not detected in supernatants from VIP-treated cells as
in the controls (data not shown). Next, we investigated the time
course of the production of these cytokines by exposing 1 mM VIP
to DJM-1 cells for various periods. IL-6, IL-8, and RANTES levels
began to increase after 6 h of exposure, and further increased up to
24 h in culture supernatants (Figs 6C, 7C, 8C). These results
indicate that IL-6, IL-8, and RANTES production by VIP is time
and dose dependent.
Western blot analysis revealed that intracellular IL-6 level was
slightly increased by 1 mM VIP at 3 h, decreased after 12 h, and
disappeared at 24 h (Fig 6D). Intracellular IL-8 markedly increased
in 1 mM VIP-treated cells from 3 h to 12 h with a peak at 6 h, and
decreased to an undetectable level at 24 h (Fig 7D).
Inhibitory effects of VIP1R antagonist on cytokine
production from VIP-treated DJM-1 cells Finally, we
examined whether VIP-induced cytokine production is mediated
via VIP1R. To this end, DJM-1 cells were cultured in the presence
of 1 mM VIP with or without 1 mM VIP1R antagonist, and
cytokine production was determined after 6 h. Figures 6(C), 7(C),
and 8(C) show that VIP1R antagonist abrogated the production of
IL-6, IL-8, and RANTES in VIP-treated DJM-1 cells. These
®ndings indicate that VIP1R mediates the production of these
cytokines.
DISCUSSION
VIP has been suggested to play an important role in skin
physiology. It is known that VIP-containing nerve ®bers exist in
the epidermis, the dermis beneath the basal membrane (Bjorklund
Figure 3. Induction of cAMP production by VIP and its
inhibition by VIP1R antagonist in DJM-1 cells and normal
human epidermal keratinocytes. After starvation, DJM-1 cells (A)
and normal human epidermal keratinocytes (B) were treated with various
concentrations of VIP for 10 min after preincubation with (gray bar) or
without (open bar) 1 mM VIP1R antagonist for 10 min at 37°C. Cells
were also treated with 1 mM forskolin (F) as a positive control.
Intracellular cAMP concentration was determined by a speci®c enzyme
immunoassay, and the results are expressed as mean 6 SD (n = 4), fmol
per well. *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 4. The effects of VIP on proliferation of DJM-1 cells. After
starvation, DJM-1 cells were incubated in the absence or presence of
0.1 nM to 1 mM VIP for 24 h in the absence of FBS. (A) Subsequently,
cells were detached using trypsin and EDTA, resuspended as single cells,
and counted. (B) DNA synthesis was evaluated by BrdU incorporation.
Results are expressed as fold increase against the pretreatment level.
Mean 6 SD (bar) is shown (n = 4). *p < 0.05 vs nontreated group.
Figure 5. The effects of various cytokines on VIP1R mRNA
expression in DJM-1 cells. After starvation, DJM-1 cells were
incubated with 10 ng per ml of either IL-4 (A), TNF-a (B), or IFN-g
(C) for indicated periods. Northern blot analysis was performed as
described in the legend to Fig 2. Ethidium bromide staining of 28 s and
18 s rRNA is shown as a loading control (D). Signal intensity of each
band was quanti®ed by densitometric analysis (E). The relative
densitometric values of VIP-treated DJM-1 cells at each time point are
expressed as a percentage of the value of untreated DJM-1 cells at 0 h.
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et al, 1986), the deeper dermis around blood vessels (Bloom and
Polak, 1983), sweat glands, and hair follicles (Pincelli et al, 1990;
Ostlere et al, 1995). VIP-positive nerve ®bers around glands in
atopic dermatitis reveal a similar pattern to healthy subjects (Pincelli
et al, 1990). Pincelli et al (1991) and Anand et al (1991), however,
pointed out an increase in the numbers of VIP-positive nerve ®bers
in skin lesions of patients with atopic dermatitis. In patients with
psoriasis, VIP-positive nerve ®bers also increase in the dermis, at
the dermo-epidermal junction, and in the epidermis compared
with nonlesional and healthy skin (Al'abadie et al, 1995). VIP levels
especially increase in chronic licheni®ed lesions of atopic dermatitis
(Anand et al, 1991; Pincelli et al, 1991; Giannetti et al, 1992) and
psoriasis (Anand et al, 1991).
VIP regulates a wide range of lymphocyte and macrophage
functions including cell adhesion (Johnston et al, 1994), migration
(Ottaway and Greenberg, 1984), and production of various
cytokines (Ganea, 1996; Tang et al, 1996). These effects are
mediated through two structurally distinct G protein-coupled
receptors (Ishihara et al, 1992; Lutz et al, 1993; Sreedharan et al,
1993; Svoboda et al, 1994), which are expressed on certain subsets
of T lymphocytes, B lymphocytes, and macrophages (Guerrero et al,
1981; Danek et al, 1983; Ottaway et al, 1983; Calvo et al, 1986).
Regarding the differences between the two types of VIP receptors,
two groups reported that signi®cantly greater concentrations of VIP
are required to activate VIP2R than VIP1R (Usdin et al, 1994;
Goetzl et al, 1998). Moreover, it has been demonstrated that
cellular responses after VIP1R activation are also different from
those after VIP2R activation (Goetzl et al, 1998). In human T
lymphocytes, VIP2R transduces chemotaxis, expression of matrix
metalloproteins 2 and 9, and consequently transmigration through
basement membranes and connective tissues, whereas it suppresses
cell proliferation and cytokine production. In contrast, VIP1R fails
to transduce T cell chemotaxis but mediates suppression of
chemotaxis and matrix metalloprotein expression elicited by some
cytokines and chemokines. Previous data demonstrated that
keratinocytes express VIP receptors (Haegerstrand et al, 1989;
Pincelli et al, 1992; Takahashi et al, 1993; Granoth et al, 2000).
VIP1R and VIP2R immunoreactivities are localized on basal
keratinocytes in the epidermis of both involved and uninvolved
skin of allergic contact dermatitis (Lundeberg and Nordlind, 1999).
Although many studies focused on VIP and VIP receptors, the
factors regulating VIP receptor expression are poorly understood.
This study demonstrated that VIP1R mRNA was expressed in
DJM-1 cells and normal human epidermal keratinocytes, and
VIP2R mRNA was detected in DJM-1 cells but not in human
epidermal keratinocytes. We also found that DJM-1 cells expressed
VIP1R predominantly over VIP2R in intensity of RT-PCR. VIP
itself enhanced the expression of VIP1R on DJM-1 cells in a time-
dependent manner. These results suggest that keratinocytes possess
VIP1R under physiologic conditions, and VIP exerts some effects,
including upregulation of its own receptor, via binding to VIP1R.
In previous studies, VIP induced the migration of human
Figure 6. IL-6 production from DJM-1 cells treated with VIP. (A)
After starvation, DJM-1 cells were stimulated with various concentrations
of VIP (0.1 nM to 10 mM), and supernatants were harvested after 6 h.
***p < 0.001, ****p < 0.0001 vs nontreated group. (B) DJM-1 cells
were cultured in the presence of 1 mM VIP for 6 h with (gray bar) or
without (open bar) 1 mM VIP1R antagonist. **p < 0.01. (C) DJM-1 cells
were incubated with 1 mM VIP for indicated periods. **p < 0.01, ****p
< 0.0001 vs control group. IL-6 concentration in the culture supernatants
of DJM-1 cells was determined by a speci®c IL-6 enzyme immunoassay.
Bars are expressed as mean 6 SD (n = 4), pg per ml. (D) Intracellular
IL-6 was determined by Western blotting using speci®c anti-IL-6
antibody. IL-6 protein was detected as a single 21 kDa band.
Figure 7. IL-8 production from DJM-1 cells treated with VIP. (A)
After starvation, DJM-1 cells were stimulated with various concentrations
of VIP (0.1 nM to 10 mM), and supernatants were harvested after 6 h.
*p < 0.05, ***p < 0.001, ****p < 0.0001 vs nontreated group. (B)
DJM-1 cells were cultured in the presence of 1 mM VIP for 6 h with
(gray bar) or without (open bar) 1 mM VIP1R antagonist. *p < 0.05. (C)
DJM-1 cells were incubated with 1 mM VIP for indicated periods.
****p < 0.0001 vs control group. IL-8 concentration in the culture
supernatants of DJM-1 cells was determined by a speci®c IL-8 enzyme
immunoassay. Bars are expressed as mean 6 SD (n = 4), pg per ml. (D)
Intracellular IL-8 was determined by Western blotting using speci®c
anti-IL-8 antibody. IL-8 protein was detected as a single 9 kDa band.
Figure 8. RANTES production from DJM-1 cells treated with
VIP. (A) After starvation, DJM-1 cells were stimulated with various
concentrations of VIP (0.1 nM to 10 mM), and supernatants were
harvested after 6 h. *p < 0.05, **p < 0.01, ***p < 0.001 vs nontreated
group. (B) DJM-1 cells were cultured in the presence of 1 mM VIP for
6 h with (gray bar) or without (open bar) 1 mM VIP1R antagonist. **p
< 0.01. (C) DJM-1 cells were incubated with 1 mM VIP for indicated
periods. ****p < 0.0001 vs control group. RANTES concentration in
the culture supernatants of DJM-1 cells was determined by a speci®c
RANTES enzyme immunoassay. Bars are expressed as mean 6 SD
(n = 4), pg per ml.
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keratinocytes and their colonization in an arti®cial polyurethane
matrix (Wollina et al, 1997), and also promoted the proliferation of
keratinocytes (Wollina et al, 1997; Sung et al, 1999). These effects
are shown to be associated with the stimulation of adenylate cyclase
activity (Haegerstrand et al, 1989; Pincelli et al, 1992; Takahashi
et al, 1993; Granoth et al, 2000). In this study, we also showed that
intracellular cAMP was markedly increased by VIP in DJM-1 cells
and normal human epidermal keratinocytes with the same levels of
increase in both cells. This increase was considered to be mediated
through VIP1R, because VIP1R antagonist abrogated VIP-
induced cAMP production. In addition, VIP induced an approxim-
ately 1.5-fold increase in cell numbers and DNA synthesis in DJM-
1 cells. This is consistent with previous reports that a 1.5- to 2.5-
fold increase in cell number was observed in VIP-treated normal
human epidermal keratinocytes and human neonatal keratinocytes
(Pincelli et al, 1992; Granoth et al, 2000). Taken together, these
data suggest the presence of an autoregulatory loop involving VIP
and VIP1R, which may underlie hyperproliferation of keratino-
cytes in certain pathologic conditions such as psoriasis and atopic
dermatitis.
In our study, both Th1 (IFN-g) and Th2 (IL-4) cytokines as well
as TNF-a enhanced the expression of VIP1R mRNA in DJM-1
cells. The kinetics of VIP1R induction was different between Th1
and Th2, however, suggesting that these cytokines regulate VIP1R
expression in distinct manners. Several reports indicate that the
presence of helper T lymphocytes, producing Th2 cytokines, in
skin lesions is characteristic of atopic dermatitis in acute phases (van
der Heijden et al, 1991). In contrast, T cells expressing IL-4 and IL-
13 mRNA (Th2 clones) are signi®cantly fewer in skin lesions of
chronic atopic dermatitis, and instead T cells expressing IFN-g and
IL-5 mRNA (Th1 clones) increase in number (Leung, 1999).
Given that both Th1 and Th2 cytokines enhanced VIP1R
expression on keratinocytes, VIP may play a role in both acute
and chronic phases of atopic dermatitis. Elucidation of the
mechanisms of VIP receptor regulation by Th1 and Th2 cytokines
will help resolve the pathophysiologic roles of VIP in atopic
dermatitis.
We also found that VIP enhanced the production of in¯amma-
tory cytokines, such as IL-6, IL-8, and RANTES, from DJM-1
cells. VIP1R antagonist abrogated the production of these
cytokines, suggesting that VIP-induced cytokine production is
also mediated through VIP1R. IL-6 is a multifunctional cytokine
produced by monocytes, T lymphocytes, ®broblasts, and epithelial
cells (Wong and Clark, 1988). IL-6 is known as an important
mediator of various immune responses and in¯ammation, and is
considered to be responsible for keratinocyte proliferation in
certain in¯ammatory dermatoses such as psoriasis (Neuner et al,
1991). In a previous paper, VIP could not induce IL-6 synthesis in
cultured human keratinocytes derived from normal foreskin and
psoriatic lesions (Park and Kim, 1999). In contrast, IL-6 production
signi®cantly increased in VIP-treated DJM-1 cells compared to the
untreated control in our study. These distinct results may be due to
the differences in experimental conditions including the incubation
time (6 h here and 24 h in the previous study) and the origin of the
cultured keratinocytes. In addition, Park and Kim reported that
recombinant human IFN-g increases IL-6 production from both
normal neonatal and psoriatic keratinocytes. According to their
data, the amounts of IL-6 induced by 24 h treatment with IFN-g
are 10 times more than those obtained by 6 h treatment with VIP.
The discrepancy between their data and ours may also be caused by
the different experimental conditions. IL-8 was isolated as a
chemotactic factor for neutrophils and T cells (Yoshimura et al,
1987; Larsen et al, 1989). In®ltration of neutrophils into the
epidermis is reported to be mediated by IL-8 in psoriasis.
Therefore, our ®ndings suggest that VIP is involved partially in
the pathogenesis of psoriasis through induction of IL-6 and IL-8
production from keratinocytes. RANTES is a chemoattractant and
activator of eosinophils (Zhang et al, 1994). Thus, VIP-induced
RANTES production from keratinocytes may be causally related to
exacerbation of atopic dermatitis and psoriasis (Lundin et al, 1990;
Kim et al, 1997), in which eosinophil chemotaxis plays an
important role in disease progression.
In summary, VIP induces production of cAMP and cytokines
and cell proliferation in keratinocytes through VIP1R, which is
upregulated in response to various in¯ammatory cytokines and VIP
itself. This network around keratinocytes may be implicated in
in¯ammatory responses in atopic dermatitis and psoriasis, and thus
is supposed to be important for prevention and treatment of these
disorders.
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